Clinical trial
A Multicentric, Retrospective, Real-Word Study to Evaluate the Efficacy and Safety of Inebilizumab Compare With Rituximab in Neuromyelitis Optica Spectrum Disorders
Name
IRNMO-001
Description
To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.
Trial arms
Trial start
2023-10-20
Estimated PCD
2024-06-30
Trial end
2025-06-30
Status
Not yet recruiting
Treatment
Inebilizumab
Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.
Arms:
Exposed group 1
Rituximab(RTX)
RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.
Arms:
Exposed group 2
Size
80
Primary endpoint
Change in Expanded Disability Status Scale Score (EDSS) from baseline.
12 months
Time to first relapse
12 months
Number of new, and/or enlarging T2- hyperintense lesions detected by Magnetic Resonance Imaging (MRI)
12 months
Eligibility criteria
Inclusion Criteria:
* 1. Age ≥ 18 years with anti-AQP4-IgG seropositive NMOSD as defined by 2015 NMOSD diagnostic criteria by IPND (International Panel for NMO Diagnosis).
* 2. Expanded disability status scale (EDSS) score ≤ 8 and ≥ 2.5 during the acute phase.
* 3. Patients have given their written informed consent.
Exclusion Criteria:
* 1. Lactating and pregnant females.
* 2. Participate in other interventional studies within 30 days or within 5 half-lives of the investigational agent before received inebilizumab and rituximab (RTX).
* 3. Receipt of any experimental B-cell depleting agent within 6 months prior inebilizumab and RTX, and B-cells below the lower limit of normal
* 4. Known history of a severe allergy or reaction to any component of the investigational product formulation.
* 5. Known active severe bacterial, viral, or other infection or any major episode of infection requiring hospitalization (including viral hepatitis, active tuberculosis or positive tuberculosis screening).
* 6. History of alcohol, drug, or chemical abuse, or a recent history of such abuse \< 1 year prior to treatment.
* 7. History of malignancies.
* 8. Combined with severe mental disorders and other conditions and unable to cooperate with follow-up.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Blood samples are collected before the treatment and at the last follow-up.'}, 'enrollmentInfo': {'count': 80, 'type': 'ESTIMATED'}}
Updated at
2023-10-05
1 organization
2 products
1 indication
Organization
Feng JinzhouProduct
InebilizumabIndication
Neuromyelitis Optica Spectrum DisordersProduct
Rituximab(RTX)